|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-5-22
|
|
pubmed:abstractText |
Patients with International Union Against Cancer (UICC) stage IIb and III colon cancer and stage II and III rectal cancer may receive adjuvant chemotherapy with 5-fluorouracil (5-FU). High levels of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) have been associated with resistance to 5-FU in advanced colorectal cancer. The aim of this study was to investigate the association of TS and DPD mRNA levels with recurrence-free survival in patients with colorectal cancer who are receiving adjuvant 5-FU-based chemotherapy. TS and DPD mRNA quantitation was retrospectively performed in primary colorectal cancer specimens from patients receiving adjuvant 5-FU using a reverse transcription- polymerase chain reaction technique. The median TS mRNA level in patients with a recurrence (n = 142) was 0.68, and in patients without a recurrence (n = 206) the median level was 0.80 (P < 0.01). Patients with a recurrence who had a low TS level (TS < or = 0.9; n = 102) had a median recurrence-free survival of 18 months (range 3.0 to 54 months), and those with a high TS level (TS > 0.9; n = 40) had a median recurrence-free survival of 11 months (range 1.7 to 53 months; P = 0.0024). There was no difference in the median recurrence-free survival of patients with low and high DPD mRNA levels. The TS mRNA level may be a useful marker to predict the time to recurrence in patients with colorectal cancer who are receiving adjuvant 5-FU treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1091-255X
|
|
pubmed:author |
pubmed-author:BaumannWolframW,
pubmed-author:BegerHans GHG,
pubmed-author:BehnkeDetlevD,
pubmed-author:GalubaIngaI,
pubmed-author:HäuslerPeterP,
pubmed-author:HeckerUteU,
pubmed-author:KettnerErikaE,
pubmed-author:KornmannMarkoM,
pubmed-author:KreuserErnst DED,
pubmed-author:LOUWJ WJW,
pubmed-author:LeiblBernhardB,
pubmed-author:LinkKarl HKH,
pubmed-author:PolatSucanS,
pubmed-author:RidwelskiKarstenK,
pubmed-author:SchützeFrankF,
pubmed-author:SchlichtingChristophC,
pubmed-author:ScholzPeterP,
pubmed-author:SchrammHaraldH,
pubmed-author:SchwabeWolfgangW,
pubmed-author:SträterJörnJ,
pubmed-author:VogtJürgen HJH,
pubmed-author:ZerbianKlaus-UllrichKU
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
331-7
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12022983-Aged,
pubmed-meshheading:12022983-Antimetabolites, Antineoplastic,
pubmed-meshheading:12022983-Chemotherapy, Adjuvant,
pubmed-meshheading:12022983-Colonic Neoplasms,
pubmed-meshheading:12022983-Dihydrouracil Dehydrogenase (NADP),
pubmed-meshheading:12022983-Disease-Free Survival,
pubmed-meshheading:12022983-Female,
pubmed-meshheading:12022983-Fluorouracil,
pubmed-meshheading:12022983-Humans,
pubmed-meshheading:12022983-Male,
pubmed-meshheading:12022983-Middle Aged,
pubmed-meshheading:12022983-Neoplasm Recurrence, Local,
pubmed-meshheading:12022983-Oxidoreductases,
pubmed-meshheading:12022983-RNA, Messenger,
pubmed-meshheading:12022983-Rectal Neoplasms,
pubmed-meshheading:12022983-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:12022983-Thymidylate Synthase
|
|
pubmed:articleTitle |
Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer.
|
|
pubmed:affiliation |
Department of General Surgery, University of Ulm, Ulm, Germany.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
